Huluwa Pharmaceutical Group's IND Application for Category 1.1 TCM New Drug Xiao'er Danqing Shuangjie Granules Accepted

Recently, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced new progress. The Investigational New Drug (IND) application for the pediatric traditional Chinese medicine "Xiao'er Danqing Shuangjie Granules", developed by Huluwa Pharmaceutical Group, has been officially accepted by the NMPA. This marks a key milestone in the staged development of this pediatric drug project.

Xiao'er Danqing Shuangjie Granules is a key product in Huluwa Pharmaceutical Group's strategic pipeline of pediatric traditional Chinese medicines. It is a Category 1.1 new traditional Chinese medicine, primarily indicated for the treatment of respiratory diseases in children, such as viral influenza. The product is based on a long-term clinical experience-based formula developed by Professor Wang Xuefeng, a nationally renowned traditional Chinese medicine expert. It has the functions of clearing heat and releasing the exterior, purging fire and detoxifying, and treating both exterior and interior conditions. It is expected to provide a new traditional Chinese medicine treatment option for pediatric patients with related diseases. As a well-known domestic pharmaceutical company focusing on children's health, Huluwa Pharmaceutical Group's pediatric product portfolio has attracted significant market attention. The advancement of the development of Xiao'er Danqing Shuangjie Granules also reflects the Group's continued commitment to innovation in pediatric-specific traditional Chinese medicine.